Joseph Christopher Murray, MD, discusses the role of prognostic markers in non–small cell lung cancer and how data from the EMPOWER trials will guide future directions in the space.
Edgardo S. Santos, MD, FACP, discusses the impact of treatment with cemiplimab plus chemotherapy in patients with squamous non–small cell lung cancer.
The FDA has granted full approval to cemiplimab-rwlc for the treatment of patients with metastatic basal cell carcinoma who previously received a hedgehog inhibitor (HHI) or for whom a HHI is not appropriate.
WASHINGTON (dpa-AFX) - Sensei Biotherapeutics, Inc. (SNSE) announced a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo. The supply agreement supports the evaluation of
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Libtayo